What is the clinical evidence from this study?

Study design: Other. Population: Thrombosis. Intervention: EL2Ab (antibody targeting P2Y1R). Primary outcome: ADP-induced platelet aggregation and thrombus formation.

January 16, 2015Arteriosclerosis Thrombosis and Vascular BiologyOpen Access

Characterization of a Novel Function-Blocking Antibody Targeted Against the Platelet P2Y1Receptor

View Full Paper

Ask AI

Bookmark

Key result

Novel P2Y1 antibody EL2Ab inhibits platelet aggregation and delays experimental thrombosis but prolongs bleeding.

Why the study?

Does EL2Ab inhibit platelet function and protect against thrombogenesis in preclinical models?

Population

Platelets and FeCl3-induced thrombosis model

Design

Preclinical

Authors

ZKZubair A. KarimAugusta University Health HVHari Priya VemanaSt. John's University FAFatima Z. AlshboolTexas A&M University – Kingsville

Discussion

Member takes

Implication

EL2Ab shows preclinical antithrombotic activity; leaves open P2Y1R as a human therapeutic target pending clinical studies.

Structured PICO

Does EL2Ab inhibit platelet function and protect against thrombogenesis in preclinical models?

Population

Platelets and FeCl3-induced thrombosis model

Intervention

EL2Ab (novel antibody targeting the second extracellular loop of the P2Y1 receptor)

Outcome

Inhibition of ADP-induced platelet aggregation and time for occlusion in a FeCl3-induced thrombosis modelsurrogate

A novel function-blocking antibody against the P2Y1 receptor inhibits platelet aggregation and thrombus formation, validating P2Y1R as a potential target for antiplatelet therapy.

Cite This Study

Karim et al. (2015) studied Thrombosis. EL2Ab (antibody targeting P2Y1R) was evaluated on ADP-induced platelet aggregation and thrombus formation. A novel antibody targeting the P2Y1 receptor (EL2Ab) dose-dependently inhibited ADP-induced platelet aggregation and prolonged occlusion time in a thrombosis model, alongside prolonged bleeding time.

synapsesocial.com/papers/6a0ecbee2eca052da647ca38 https://doi.org/10.1161/atvbaha.114.304509

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

January 16, 2015Arteriosclerosis Thrombosis and Vascular BiologyOpen Access

Characterization of a Novel Function-Blocking Antibody Targeted Against the Platelet P2Y1Receptor

View Full Paper

Ask AI

Bookmark

Key result

Novel P2Y1 antibody EL2Ab inhibits platelet aggregation and delays experimental thrombosis but prolongs bleeding.

Why the study?

Does EL2Ab inhibit platelet function and protect against thrombogenesis in preclinical models?

Population

Platelets and FeCl3-induced thrombosis model

Design

Preclinical

Authors

ZKZubair A. KarimAugusta University Health HVHari Priya VemanaSt. John's University FAFatima Z. AlshboolTexas A&M University – Kingsville

Discussion

Member takes

Implication

EL2Ab shows preclinical antithrombotic activity; leaves open P2Y1R as a human therapeutic target pending clinical studies.

Structured PICO

Does EL2Ab inhibit platelet function and protect against thrombogenesis in preclinical models?

Population

Platelets and FeCl3-induced thrombosis model

Intervention

EL2Ab (novel antibody targeting the second extracellular loop of the P2Y1 receptor)

Outcome

Inhibition of ADP-induced platelet aggregation and time for occlusion in a FeCl3-induced thrombosis modelsurrogate

A novel function-blocking antibody against the P2Y1 receptor inhibits platelet aggregation and thrombus formation, validating P2Y1R as a potential target for antiplatelet therapy.

Cite This Study

synapsesocial.com/papers/6a0ecbee2eca052da647ca38 https://doi.org/10.1161/atvbaha.114.304509

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark